- The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD
- The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions
- 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects
Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies like Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been ongoing, partly charging what has come to be referred to as the psychedelic renaissance.
Research has so far shown that the drugs – ketamine, psilocybin, MDMA (also known as ecstasy), and LSD – could potentially remedy mental conditions such as post-traumatic stress disorder (“PTSD”), depression, and addiction. There is also growing evidence that psychedelic drugs’ action in the brain differs from addictive drugs’ (https://nnw.fm/s9EUH).
“One of the key mooted advantages of psychedelics over existing drugs is that they work holistically to make the neuroplastic brain more malleable, therefore freeing people from long-held beliefs and memories – opening them evermore to new concepts and states of mind. Thus, they allow the brain to reset and rewire itself, rather than simply dampening down symptoms and even causing serious side-effects,” reads an article published in The Guardian (https://nnw.fm/YkLUf).
In describing this family of promising medicines, Delic Co-founder and CEO Matt Stang similarly highlighted their “potential to be more effective than traditional drugs with minimal side effects, giving people their best lives back.” Stang’s comments are contained in a recent announcement in which Delic, a company making a mark in the psychedelic wellness scene, reported the findings of a survey it had commissioned (https://nnw.fm/nLvnx).
According to the survey conducted by The Harris Poll, 65% of Americans who suffer from anxiety/depression/PTSD believe that psychedelic medicine (ketamine, psilocybin, and MDMA) should be made available to patients with treatment-resistant anxiety, depression, or PTSD.
Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings of anxiety, depression, or PTSD. Eighteen percent also said the prescribed drugs worsened their condition or did not improve it at all.
Eighty-three percent of Americans living with anxiety, depression, or PTSD would be open to pursuing alternative treatments proven to be more effective than prescription medication with fewer side effects. More specifically, 66%, 62%, and 56% would be open to pursuing treatment using ketamine, psilocybin, and MDMA, respectively, if each was proven more effective than prescription drugs with fewer side effects.
“We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and lawmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” added Stang.
The survey was conducted online within the United States in early December among 2,037 adults aged 18 or older, 953 of whom suffer from anxiety/depression/PTSD. It was not based on probability sampling.
Founded in 2018, Delic is a leader in new medicines and treatments for a modern world and is committed to providing education, research, and treatment options to the masses in the field of psychedelics through an umbrella of related businesses that includes the largest chain of psychedelic wellness clinics with Ketamine Wellness Centers (“KWC”) and Ketamine Infusion Centers (“KIC”); media properties Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on the R&D of psilocybin vaporization products; and Meet Delic, the largest psychedelic wellness event.
For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://nnw.fm/DELCF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
